The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with capsules, 20 cm2 patches markedly increased cognitive scores and had tolerability similar to that of capsules.430”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [430]
In the citing paper
“Importantly, the incidences of nausea (7.2% vs. 23.1%) and vomiting (6.2% vs. 17.0%) were lower than those in the placebo group.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [430]
In the citing paper
“The results showed that rivastigmine had significant efficacy in the treatment group compared with the placebo group and that the efficacy of the 10 cm2 patch was similar to that of the capsules.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [430]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Research works printed but not linked: 16
- 10.1517/13543784.6.12.1887 · DOI
- 10.1002/gps.1788 · DOI · Paper page
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.1176/ajp.141.11.1356 · DOI · Paper page
- 10.1097/00002093-199700112-00004 · DOI · Paper page
- 10.1097/00002093-199700112-00005 · DOI · Paper page
- 10.1111/j.1532-5415.1993.tb07308.x · DOI · Paper page
- Corrigan JD, Hinkeldey NS. Relationship between part A and B of the Trail Making Test. J Clin Psychiatr 1987;43:402–409.
- 10.1016/S0011-393X(98)85048-0 · DOI
- Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65.
- Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2000;2:68–72.
- 10.1097/00002093-200108001-00003 · DOI
- 10.1002/gps.496 · DOI
- Gauthier S, Bruno V, Farlow M, Burn D. Aggressive course of disease in dementia. Alzheimers Dement. 2006;2:210–217.
- Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999;318:633–638.
- Blesa R, Ballard C, Orgogozo J-M, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007;69(Suppl 1):S23–S28.
Cited by
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
Donepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trial
Mori, E., Ikeda, M., Kosaka, K., & on behalf of the Donepezil‐DLB Study Investigators (2012) · Annals of Neurology · doi:10.1002/ana.23557 · Cited by 274
Metadata
- Authors
- Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R.
- Venue
- Neurology
- Published
- 2007-07-24
- Volume
- 69
- Issue
- 4_suppl_1
- ISSN
- 0028-3878
- 1526-632X
- Cited by
- 136
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000281847.17519.e0
- The paper
- Winblad, B., Grossberg, G., Frölich, L., Farlow, M., Zechner, S., Nagel, J., & Lane, R. (2007). IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000281847.17519.e0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
